Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CD7-H522b | Human | Human CD27 / TNFRSF7 Protein, His Tag (MALS Verified) |  |
|
|
| CD7-M5252 | Mouse | Mouse CD27 / TNFRSF7 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| CD7-H5257 | Human | Human CD27 / TNFRSF7 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| CD7-C5259 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque CD27 / TNFRSF7 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| TN7-H82F6 | Human | Biotinylated Human CD27 / TNFRSF7 Protein, Fc,Avitag™ |  |
|
|
| CD7-H5254 | Human | Human CD27 / TNFRSF7 Protein, Fc Tag (HPLC verified) |  |
|
|
Flow Cytometry assay shows that Human CD27, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD7-H5257) can bind to Raji cells Surface Human CD70. The concentration of CD27 used is 10 μg/mL (Routinely tested).
Immobilized Mouse CD27, Mouse IgG2a Fc Tag (Cat. No. CD7-M5252) at 2 μg/mL (100 μL/well) can bind Biotinylated Mouse CD70, His Tag, Avi Tag with a linear range of 1-16 ng/mL (QC tested).
The purity of Human CD27, His Tag (Cat. No. CD7-H522b) was more than 85% and the molecular weight of this protein is around 38-48 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Anti-CD27 monoclonal antibody (Aduro Biotech) | BION-1402 | Phase 1 Clinical | Aduro Biotech | Neoplasms | Details |
| LOR-S03 | CDX-527; LOR-A04; LOR-S01; LOR-S03 | Phase 1 Clinical | Celldex | Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Varlilumab | CDX-1127 | Phase 2 Clinical | Celldex | Urologic Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Urogenital Neoplasms; Lymphoma; Glioma; Lymphoma, Non-Hodgkin; Urologic Neoplasms; Lymphoma, Mantle-Cell; Prostatic Neoplasms; Ovarian Neoplasms; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Kidney Diseases; Glioblastoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Kidney Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell; Solid tumours | Details |
| MK-5890 | MK-5890 | Phase 2 Clinical | Merck & Co Inc | Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.
A-Z